OR WAIT null SECS
Unnamed US facility will increase company's manufacturing capacity
Due to an increase in customer demand for commercial scale 2000L single use bioreactors across various therapeutic sectors, Abzena will add a sixth global site that will expand current good manufacturing practice (cGMP) manufacturing capacity for mammalian biologics, the life sciences group says.
Construction of the site is expected to begin mid-2022.
The new facility will be in the US and will be home to Phase III and commercial manufacturing. A phased approach to construction will initially allow four modular suites, with each suite including up to two 2000L bioreactors, followed by the addition of two further 2000L suites.